COVID-19谜题:解读新型疾病实体的病理生理与表型
该综述探讨COVID-19的病理生理、表型及抗SARS-CoV-2宿主反应,指出重症常累及呼吸系统但多系统受累且急性期后迁延并发症常见;证据提示COVID-19为以内皮病变为中心的新型疾病实体,需基础与临床研究进一步阐明机制以优化诊疗。
要点
- 重症COVID-19以呼吸系统表现为主,但多系统受累且急性期后并发症迁延。
- SARS-CoV-2可导致宿主反应失调,引发免疫炎症、血栓及实质损伤。
- 证据提示COVID-19为以内皮病变为中心的新型疾病实体。
核心结论
- COVID-19构成一种新型疾病实体,证据提示其病理生理以内皮病变为中心。
研究设计与样本
- 综述,总结COVID-19病理生理、表型及体液与细胞水平抗SARS-CoV-2宿主反应。
主要发现
- 重症COVID-19最常见呼吸系统表现,其他系统亦受累,急性病后常迁延并发症。
- SARS-CoV-2失调宿主反应,引发广泛免疫炎症、血栓及实质损伤。
- COVID-19与其他原因呼吸衰竭有相似之处,但许多机制特征具独特性。
临床怎么用
- 临床应认识COVID-19多系统受累及迁延并发症,关注内皮病变相关病理生理。
局限性
- 需进一步基础与临床研究以阐明病理生理机制并刻画各表型免疫炎症失调。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The zoonotic SARS-CoV-2 virus that causes COVID-19 continues to spread worldwide, with devastating consequences. While the medical community has gained insight into the epidemiology of COVID-19, important questions remain about the clinical complexities and underlying mechanisms of disease phenotypes. Severe COVID-19 most commonly involves respiratory manifestations, although other systems are also affected, and acute disease is often followed by protracted complications. Such complex manifestations suggest that SARS-CoV-2 dysregulates the host response, triggering wide-ranging immuno-inflammatory, thrombotic, and parenchymal derangements. We review the intricacies of COVID-19 pathophysiology, its various phenotypes, and the anti-SARS-CoV-2 host response at the humoral and cellular levels. Some similarities exist between COVID-19 and respiratory failure of other origins, but evidence for many distinctive mechanistic features indicates that COVID-19 constitutes a new disease entity, with emerging data suggesting involvement of an endotheliopathy-centred pathophysiology. Further research, combining basic and clinical studies, is needed to advance understanding of pathophysiological mechanisms and to characterise immuno-inflammatory derangements across the range of phenotypes to enable optimum care for patients with COVID-19.
引用
- Osuchowski MF, Winkler MS, Skirecki T, et al. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med. 2021. PMID: 33965003. doi:10.1016/S2213-2600(21)00218-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。